Targeting Cell Survival Pathways to Enhance Response to Chemotherapy /

"Targeting Cell Survival Pathways to Enhance Response to Chemotherapy encompasses recently developed molecular targeting agents and approaches that suppress cell survival signaling. Cell survival signaling attenuates the effectiveness of conventional chemotherapy and numerous mechanisms have be...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Johnson, Daniel E. (Professor) (Autor)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: London, United Kingdom : Academic Press, an imprint of Elsevier, [2018]
Colección:Cancer sensitizing agents for chemotherapy ; v. 3.
Temas:
Chemotherapy.
Drug targeting.
Molecular Targeted Therapy
Neoplasms > drug therapy
Antineoplastic Agents > therapeutic use
Drug Therapy
Drug Delivery Systems
Chimioth�erapie.
M�edicaments > Ciblage.
MEDICAL > Pharmacology.
Chemotherapy
Drug targeting
Internet Resources.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Cover; Title Page; Copyright Page; Dedication; Contents; List of Contributors; Author Biography; Preface; Chapter 1
  • Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy; Abstract; 1.1
  • Introduction; 1.2
  • HER Family Receptors; 1.2.1
  • EGFR; 1.2.2
  • HER2; 1.2.3
  • HER3; 1.2.4
  • HER4; 1.3
  • Conclusions; Abbreviations; Acknowledgements; References; Chapter 2
  • Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies; Abstract; 2.1
  • Discovery and Structure of Hepatocyte Growth Factor.
  • 2.2
  • Activation of the HGF-MET Signaling Pathway2.2.1
  • Mitogen-Activated Protein Kinase Cascades; 2.2.2
  • PI3K-Akt; 2.2.3
  • STAT3; 2.2.4
  • HGF-Independent Activation and cMET Internalization; 2.2.5
  • Receptor Shedding; 2.3
  • HGF Functions; 2.3.1
  • Placenta; 2.3.2
  • Muscle; 2.3.3
  • Liver; 2.3.4
  • Kidney; 2.3.5
  • Nervous System; 2.3.6
  • Testis; 2.4
  • Dysregulation in Cancer; 2.4.1
  • cMET Mutations; 2.4.2
  • Amplification and Fusion Protein of cMET; 2.4.3
  • cMET Overexpression; 2.4.4
  • HGF Overexpression; 2.5
  • HGF Inhibitors for Cancer Therapy; 2.5.1
  • HGF Activation Inhibitors.
  • 2.5.2
  • HGF Inhibitors2.5.3
  • MET Antagonists; 2.5.4
  • MET Kinase Inhibitors; 2.6
  • Targeting HGF-cMET Pathway in Solid Tumors to Overcome Drug Resistance; 2.6.1
  • Lung Cancer; 2.6.2
  • Renal Cancer; 2.6.3
  • Pancreatic Ductal Adenocarcinoma; 2.6.4
  • Colorectal Cancer; 2.7
  • Biomarkers for HGF/MET Inhibitors; 2.8
  • Conclusions and Future Directions; Abbreviations; Acknowledgments; References; Chapter 3
  • Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies; Abstract; 3.1
  • Introduction; 3.2
  • Roles for TAM RTKs in Tumorigenesis.
  • 3.2.1
  • TAM Receptor Expression and Signaling in Cancer3.2.2
  • Role of TAM RTKs in Mediating the Epithelial-to-Mesenchymal Transition; 3.2.3
  • Role of TAM RTKs in Angiogenesis; 3.3
  • Resistance to Therapy Mediated by TAM RTKs; 3.3.1
  • Role of TAM RTKs in Mediating Resistance to Traditional Chemotherapy; 3.3.2
  • Role of TAM RTKs in Mediating Resistance to Targeted Therapies; 3.3.3
  • Role of TAM RTKs in Immunosuppression; 3.4
  • Targeting AXL and Mertk; 3.4.1
  • Agents and Approaches to Inhibit TAM RTKs; 3.4.2
  • TAM RTKs as Dual Targets; 3.4.3
  • TAM RTK Biomarkers; 3.5
  • Summary; Abbreviations.

Ejemplares similares